Clinical Trial Update: IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating IN10018 in combination with pegylated liposomal doxorubicin versus PLD with placebo in platinum-resistant recurrent ovarian cancer is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• IN10018
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: InxMed (Shanghai) Co., Ltd. | Conditions: Ovarian Cancer Recurrent | Phase 2 | Status: RECRUITING